ESSA Pharma (EPIX) won near-unanimous shareholder approval for its acquisition by XenoTherapeutics.
The transaction remains subject to the approval of the Supreme Court of British Columbia and other closing conditions, ESSA said Monday in a statement.
The court hearing for the final order is scheduled for Tuesday, and the buyout is expected to be completed around Thursday.